Overview

* Assertio Holdings ( ASRT ) Q2 net product sales fall to $28.8 mln from $30.7 mln yr ago

* Adjusted EBITDA for Q2 rises to $5.6 mln, beating analyst expectations, per LSEG data

* Co narrows full-year guidance for net product sales and adjusted EBITDA

Outlook

* Company narrows full-year net product sales guidance to $108 mln-$118 mln

* Assertio ( ASRT ) updates full-year adjusted EBITDA guidance to $11 mln-$19 mln

* Company focuses investment on core assets to enhance growth potential

* Assertio ( ASRT ) ceases Otrexup commercialization to improve operational efficiencies

Result Drivers

* ROLVEDON DEMAND - Highest customer demand since acquisition, driven by strong commercial execution

* SYMPAZAN GROWTH - Increased prescriber base and prescription demand, supported by additional sales efforts

* INDOCIN DECLINE - Sales impacted by generic competition, affecting both volume and pricing

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $0.02 -$0.08

Adjusted (5

EPS Analysts

)

Q2 EPS -$0.17

Q2 Net -$16.40

Income mln

Q2 Beat $5.60 $2.71

Adjusted mln mln (3

EBITDA Analysts

)

Q2 -$8.04

Income mln

From

Operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Assertio Holdings Inc ( ASRT ) is $3.00, about 75.7% above its August 8 closing price of $0.73

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)